Antiatherogenic properties of high-density lipoproteins from arterial plasma are attenuated as compared to their counterparts of venous origin.

BACKGROUND AND AIMS High-density lipoprotein (HDL) particles play atheroprotective roles by their ability to efflux cholesterol from foam cells and to protect low-density lipoproteins (LDLs) from oxidative damage in the arterial intima. We hypothesized that antioxidative properties of HDLs can be attenuated in the oxygen-rich prooxidative arterial environment, contributing to the development of atherosclerosis. To evaluate this hypothesis, we compared antioxidative activity of HDLs from arterial and venous plasmas. METHODS AND RESULTS Arterial and venous blood samples were simultaneously obtained from 16 patients (age 68 ± 10 years; 75% males) presenting with ischemic or valvular heart disease. Major HDL subfractions and total HDLs were isolated by density gradient ultracentrifugation and their chemical composition and the capacity to protect LDLs from in vitro oxidation were evaluated. HDL-cholesterol, triglycerides and apolipoprotein (apo) B-100 levels were slightly but significantly reduced by -4 to -8% (p < 0.01) in the arterial vs. venous samples. Total mass of HDL subpopulations was similar and HDL subpopulations did not reveal marked compositional differences between the arterial and venous circulation. Potent antioxidative activity of the small, dense HDL3c subpopulation was significantly reduced in the particles of arterial origin vs. their counterparts from venous plasma (increase of +21% in the propagation rate of LDL oxidation, p < 0.05). Interestingly, antioxidative properties of venous HDLs were enhanced in statin-treated patients relative to untreated subjects. CONCLUSION Antioxidative properties of small, dense HDLs from arterial plasma are attenuated as compared to the particles of venous origin, consistent with the development of atherosclerosis in the arterial wall.

• Publication year

  2019

• Venue

  NMCD. Nutrition Metabolism and Cardiovascular Diseases

• Publication date

  2019-08-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.NUMECD.2019.07.022PMID 31753791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins.

  2018cited by this paper
• Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit

  2017cited by this paper
• Virtually same oxidizability of LDL but higher Lp(a) levels in arterial compared to venous plasma.

  2014cited by this paper
• Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.

  2013cited by this paper
• Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids: Relevance to Cellular Cholesterol Efflux, Antioxidative, Antithrombotic, Anti-Inflammatory, and Antiapoptotic Functionalities

  2013cited by this paper
• Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities

  2010cited by this paper
• A systematic review and meta‐analysis on the therapeutic equivalence of statins

  2010cited by this paper
• The LDL receptor.

  2009cited by this paper
• HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis

  2009cited by this paper
• Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis

  2006cited by this paper
• Pitavastatin

  2005cited by this paper
• Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia

  2005cited by this paper
• Antiinflammatory Properties of HDL

  2004cited by this paper
• Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

  2004cited by this paper
• Comparison of lipid and non-lipid markers of atherosclerosis in arterial versus venous blood

  2003cited by this paper
• Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress

  2003cited by this paper
• Endothelial dysfunction and atherosclerosis: Endothelin receptor antagonists as novel therapeutics

  2000cited by this paper
• Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.

  2000cited by this paper
• Oxidative modification and antioxidant protection of human low density lipoprotein at high and low oxygen partial pressures.

  1995cited by this paper
• The discovery and development of HMG-CoA reductase inhibitors.

  1992cited by this paper
• Arterial blood derived low density lipoprotein increases platelet aggregation and macrophage cholesterol content in comparison to lipoprotein derived from veinous blood.

  1989cited by this paper
• Reduced plasma high-density lipoprotein and increased platelet activity in arterial versus venous blood.

  1987cited by this paper
• Arteriovenous lipid content difference in patients with atherosclerosis.

  1985cited by this paper
• Arteriovenous lipid content difference in patients with atherosclerosis.

  1985cited by this paper
• A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum.

  1981cited by this paper

• Plasma dyslipidemia: pathogenesis and diagnostic value. Literature review

  2023cites this paper
• The influence of high-density lipoprotein (HDL) and HDL subfractions on insulin secretion and cholesterol efflux in pancreatic derived β-cells

  2021cites this paper
• High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis.

  2021cites this paper
• Suppression of serum lipid transfer proteins involved in high-density lipoprotein cholesterol metabolism by intensive insulin therapy in the first year of type 1 diabetes mellitus: Prospective InLipoDiab1 study.

  2020cites this paper